Coronary artery disease (CAD) is predicted to be the most common cause of death and disability globally by 2020 1 . Early detection and management of coronary artery disease can improve CAD related morbidity and mortality. Coronary angiogram remains the final diagnostic procedure for CAD. The current treatment strategy for CAD is confined mainly on disease of the epicardial coronary arteries. But, normal epicardial coronary arteries are found in 20% of cases undergoing coronary angiography for chest pain evaluation 2 . Detection of normal coronary arteries in patients having angina pectoris does not exclude further coronary events; rather these patients bear more risk of future cardiac ischemic syndromes. Several studies tried to discover the dilemma of non-obstructive CAD.
Fig.-1: Differences in myocardial ischemia caused by a significant coronary stenosis (A) or by CMVD (B). In the case of an epicardial (Epi) stenosis, myocardial ischemia diffusely involves the whole myocardial (usually subendocardial) territory supplied by the vessel (gray area), thus resulting in regional contractile dysfunction. In the case of microvascular alterations, myocardial ischemia is likely localized only in small myocardial areas, patchily diffused in the myocardium (small circles); this may not result in detectable contractile abnormalities because of the presence of normal contractile myocardial cells in the same territory. Also in this case, ischemia more easily occurs in subendocardial regions (more intense gray color of the small ischemic areas).
[Endo indicates endocardial. a and b indicate dysfunctional microvessels; P1 and P2-intracoronary pressure proximal and distal to obstructive vessels.] 6 microvascular disease will develop clinically evident CAD within 10 year 9 . Women Ischemic Symptom Evaluation (WISE) trial found that more than two-fold increase in cardiovascular events in women with persistence of chest pain without obstructive coronary artery 10 .
Pathophysiological Mechanisms:
The pathogenesis of this dysfunction is still speculative. Some studies argued for functionally or anatomically abnormal coronary microcirculation 4, 11, 12 . Structural abnormalities include smooth muscle hypertrophy 3 and suggested functional abnormalities are primary impairment of vascular smooth muscle cell relaxation due to reduced endothelium-dependent (nitric oxide release) and endothelium-independent vasodilators (e.g., adenosine, dipyridamole, papaverine) [13] [14] [15] . Other studies suggest basal microvascular constriction 16 and a blood steal phenomenon by normal microvessels 17 . This pathophysiology of microvascular disease explains slow flow at coronary microvascular bed. Abnormal pain perception [18] [19] [20] or a metabolic disorder affecting the handling of energy substrates by the heart muscle 21 are also suggested explanations for pain in these patients.
Causes of CMVD
Common cardiovascular risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking) are thought to cause CMVD 22 and Increased cardiac adrenergic activity can play a significant pathogenetic role in patients with stable MVA 23 . Other potential causes of CMVD, reported in several studies, include increased insulin resistance, which may facilitate endothelial activation and dysfunction 24 , estrogen deficiency in women 25 , enhanced activity of the membrane sodium-hydrogen exchanger 26 and more recently, subclinical inflammation 27, 28 .
Diagnosis
At present, the diagnosis of MVA requires clinical suspicion and exclusion of epicardial abnormalities by coronary angiography 6 . In angina patients suspected to have MVA, however, attempts should be made not only to rely on this exclusion criterion for the diagnosis but to obtain objective evidence of CMVD.
Angina symptoms are often indistinguishable from those caused by obstructive CAD.
But suspicion should be made for MVA if-
• Chest pain persists for several minutes after effort is interrupted and/or shows poor or slow response to nitroglycerin 29, 30 .
• Induction of angina and ST segment depression, but not left ventricular contractile abnormalities, during stress echocardiography 31, 32 .
• An earlier appearance of ECG abnormalities and/or angina during an exercise test performed after sublingual nitrate administration 33 .
• In case of vasospastic angina symptoms can be fully prevented by vasodilator therapy. Suspicion of coexisting MVA should be made when patients continue to experience typical effort angina despite full control of coronary artery spasm 34 .
Available diagnostic modalities for CMVD and their limitations:
Various noninvasive as well as invasive modes were tried to assess microcirculation but failed to yield a consistent result and there is hardly any simple method available at present [35] [36] [37] .
Lanza and Crea (2010) described that exercise ECG changes were usually unremarkable for the diagnosis of CMVD.
Tests to explore both the vasodilator and vasoconstrictor activity of coronary microcirculation are often proposed which can be done by invasive or non-invasively.
• A complete invasive evaluation, with intracoronary Doppler recording during CAG, would be complex and time-consuming and imposes unjustified adjunctive risks to patient.
• Whereas, a noninvasive tests, Transthoracic echocardiographic Doppler recording (TTE-DR) of coronary blood flow is easy to perform, reproducible, largely available, and, possibly, inexpensive 38 . But TTE-DR cannot identify mild CMVD and cannot explore coronary territories other than LAD 6 Contrast stress echocardiography is a promising method to detect CMVD in different myocardial territories. But there is scarcity of studies to support its applicability 6 .
Cardiac Magnetic Resonance (CMR) imaging with pharmacological stress tests and gadolinium (as a flow tracer) is perhaps the most promising method for noninvasive assessment of CMVD. At present, however, CMR seems to be too expensive, complex and timeconsuming technique to use it in routine practice 38 .
Myocardial perfusion imaging by scintigraphic stress test (SPECT, PET) is the most reliable tool available to diagnose myocardial perfusion and CMVD. But it is expensive and not easily available for routine use 6 .
The objective documentation of myocardial ischemia in patients with CMVD may be obtained with the use of certain other sophisticated diagnostic methods, which, however, cannot be proposed for routine application at present.
Assessment of lipid peroxidation products in the coronary sinus after stress tests seems to be sensitive 30 ; but it involves unjustified increased risk for the patient and are impractical for routine use.
CMR spectroscopy can detect ischemic abnormalities of phosphorus metabolism under stress tests 40 ; however, this technique is expensive, has scarce availability, and can only explore the anterior wall of the heart. 
Therapeutic Approach
Treatment of patients with microvascular disease should focus on pathophysiologic mechanisms that contribute to endothelial dysfunction, with emphasis on smoking cessation, lipid and glycemic management and blood pressure control. Conventional anti-ischemic therapy may control symptoms in some patients, but overall results are usually mixed because the fact of the limited knowledge of its causes 29 .
Traditional anti-ischemic drugs are the first step of medical treatment. β-Blockers seem rational approach because the dominant symptom is effort-related angina; particularly in patients with evidence of increased adrenergic activity (e.g., high heart rate at rest or during low-workload exercise). Calcium antagonists and nitrates have shown conflicting results in clinical trials and are more helpful in addition to β-blockers in the case of insufficient control of symptoms 47 .
Short-acting nitrates can be used to treat anginal attacks, but often they are only partially effective 29, 30 .
In patients with persisting symptoms despite optimal antiischemic therapy, several alternative forms of treatment have been proposed. ACEI (and possibly ARB) may improve microvascular function by counteracting the vasoconstrictor and prooxidant effects of angiotensin-II; particularly, in patients with hypertension or diabetes mellitus 48 .
Statins 49 & estrogens 25 improve endothelial function, thus improve anginal symptoms. These drugs can be considered in patients with hypercholesterolemia and in menopausal women, respectively.
In patients with angina refractory to various combinations of the previous medications, significant enhanced cardiac pain sensitivity is likely to be present, 19, 20 which could benefit from some other forms of treatment viz. Xanthine derivatives (aminophylline-adenosine antagonists). 17 Alternatively, the pure visceral pain inhibitor imipramine could be used to treat "refractory MVA" 50 .
